Ms. Lacks’s family accused Novartis of profiting from her cells, which were taken from her without her consent in 1951, when ...

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat ...

Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as ...

Scientists in Brazil are refining the design of CAR-engineered immune cells to make them more precise and powerful against cancer.

Since scientists first discovered that human immune cells could be modified to become cancer-fighting agents, they've been trying to engineer a cell that's effective against solid tumors, which ...

Inducement Grant In connection with the appointment of Mr. Huston as Artiva's Chief Financial Officer, Artiv’s Board of Directors approved a new employment inducement grant to Mr. Huston of 220,000 ...

For traditional cellular therapies like chimeric antigen receptor T-cell and NK-cell infusions, this "preconditioning" is vital to clear a biological path, removing endogenous cells that would ...

Zelluna has received the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) approval for its clinical trial application (CTA) to start the ZIMA-101 first ...

Nkarta Inc. company and executive profile by Barron's. View the latest NKTX company infomation and executive bios.

Researchers at the Ribeirao Preto Blood Center and the Center for Cell-Based Therapy (CTC) conducted a study using the NK-92 ...

Soon-Shiong said that ImmunityBio has also initiated the process of establishing a “world bank of natural killer cells. ・ImmunityBio recently partnered with Accord Healthcare to expand access to ...